Every material Form 8-K CapsoVision, Inc has filed with the SEC since August 17, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
CapsoVision said the U.S. Food and Drug Administration cleared AI Highlights, an AI-assisted reading feature for its CapsoCam Plus capsule endoscopy system, on September 25, 2026. The company announced the clearance on September 28, 2026, and the filing contains no revenue, profit, or guidance figures, so its direct financial effect on shareholders is not quantified.
FDA clearance received September 25, 2026; announced September 28, 2026
Tool flags suspected abnormal lesions in small bowel capsule studies to reduce physician review time
Intended for adult and pediatric patients over two years old with suspected small bowel bleeding; does not replace gastroenterologists' diagnosis
On September 17, 2026, CapsoVision agreed to sell 3,163,444 common shares at $5.69 each in a registered direct offering with no underwriter, for gross proceeds of about $18 million before expenses. The price is about 5% below the September 16 Nasdaq closing price, and all buyers are existing stockholders, including two related persons whose purchases the audit committee approved. The offering is expected to close on or about September 18, 2026, and the company will use the proceeds for general corporate purposes, which increases the number of shares outstanding.
3,163,444 shares offered at $5.69 each, a discount of about 5% to the September 16, 2026 Nasdaq closing price
Gross proceeds of about $18 million before offering expenses
Eliyahou Harari, a related person, is buying 1,757,469 shares for about $10.0 million; Star One Global Capital Limited is buying 878,734 shares for about $5.0 million
Expected closing on or about September 18, 2026; proceeds go to sales and marketing, research and development, general and administrative matters, and working capital
CapsoVision, Inc. entered into a Controlled Equity Offering sales agreement with Cantor Fitzgerald & Co. on August 13, 2026, allowing it to sell up to $100 million of common stock from time to time at its discretion. The filing discloses a legal opinion and registration details but no sales have been reported, and the filing does not state the company's use of proceeds or any financial results.
Sales agreement dated August 13, 2026 with Cantor Fitzgerald & Co. as sales agent or principal
Aggregate offering price of up to $100,000,000 of common stock, par value $0.001 per share
Shares sold under Form S-3 registration statement (File No. 333-298315) filed August 13, 2026
Legal opinion from O'Melveny & Myers LLP dated August 13, 2026, filed as Exhibit 5.1
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CapsoVision, Inc filing is on SEC EDGAR ↗. 8-K briefs of other companies →